Tifcemalimab
替西利单抗
Report date: 2026/04/30 20:00:20
Base Information
Drug NameTifcemalimab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[15]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[14]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Junshi Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesHenan Provincial People'S HospitalTopalliance Biosciences IncShanghai Pulmonary Hospital +[10]
Inactive CompaniesSichuan University
Active Indications +[14]
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A